anti-HER2 CAR T-cell therapy PD-1/TIM-3 repressed (Refuge Biotechnologies)

N/A

Report date: 2025/01/26 19:00:40

Base Information

Drug Nameanti-HER2 CAR T-cell therapy PD-1/TIM-3 repressed (Refuge Biotechnologies)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsOvarian NeoplasmsGlioblastoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRefuge Biotechnologies Inc

China Registration ClassN/A

Develop Information

Active CompaniesRefuge Biotechnologies Inc

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsGlioblastoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A